Silk Road Medical — Conference Presentation (January 2021)
22 slides from Silk Road Medical's conference presentation, Jan 12, 2021
Slide 1: Silk Road Medical January 2021
SILKROAD> MEDICAL® JANUARY 2021
Slide 2: Forward Looking Statement
Forward Looking Statement Certain information contained in this presentation and statements made orally during presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and Silk Road's own internal estimates and research. While Silk Road b
Slide 3: Ushering in a new era of minimally-invasive transcarotid therapies
SILIKKROAD> MEDICAL*® Ushering in a new era of minimally-invasive SILKROAD> 8 3 MEDICAL* transcarotid therapies % g In é "mational Expansi™ Ml SILKROAD> MEDICAL’
Slide 4: $5.1B Global TCAR Opportunity
$5.1B Global TCAR Opportunity Market Strategy Convert current procedures $1 1B we Established market with suboptimal treatments 432K Diagnoses <y $707M High Surgical Risk, ~2/3 or 110K procedures 266K $360M Standard Surgical Risk, ~1/3 or 56k procedures “ Monitored? $1.7B 2 Treat today’s untreated T
Slide 5: Carotid Artery Disease
Carotid Artery Disease — 33% of Ischemic Strokes oN pa Plaque fragments break off and move to brain I . people in US have carotid stenosis Dice wasteccoe rere E ROAD
Slide 6: New Era of Minimally-Invasive Transcarotid Therapies
New Era of Minimally-Invasive Transcarotid Therapies SURGICAL: ENDOVASCULAR: TransCarotid Artery Carotid Endarterectomy Transfemoral Carotid Artery Revascularization (TCAR) (CEA) Stenting (CAS) A New Era 65 years Since the ‘90s Crossing the lesion ~13% ~82% of procedures of procedures J ! Crossing t
Slide 7: TCAR Portfolio
TCAR Portfolio Paradigm Shift to Transcarotid ——__ ENHANCE® = ae Transcarotid Peripheral i Access Kit Direct Carotid Access c ENROUTE® Transcarotid Neuroprotection System (NPS) Helps Protect the Brain During the Procedure ENROUTE® Transcarotid Stent System Helps Protect the Brain Robust Flow Reversa
Slide 8: ENROUTE Stent & Transcarotid Neuroprotection System in Action
ENROUTE® Stent & Transcarotid Neuroprotection System in Action Venous Return Sheath —— ENROUTE® Tra id Stent System Baan ENROUTE NPS Arterial Sheath Exposed filter with emboli Flow Controller with 200um filter Ml SILKROAD> . MEDICAL’
Slide 9: The proof is in the filter
The proof is in the filter TCAR procedures worldwide’ sad Medical Third Quarter 2020 Earnings Call on November 10, 2020 k= ~~ SILKROAD> MEDICAL*
Slide 10: Momentum in U.S. Carotid Artery Disease Market
10 Momentum in U.S. Carotid Artery Disease Market Sustained = Adoption Training and + & Commercialization Expertise Cost Effective, + 2) Efficient Procedure Mounting Wave of Clinical Evidence Ml SILKROAD> MEDICAL*
Slide 11: Relentless Focus on Patient Outcomes
Relentless Focus on Patient Outcomes Every patient. Every day. MEE SILKROAD?
Slide 12: Ongoing Validation of TCAR
2 Ongoing Validation of TCAR r— Compelling Outcomes'?3 — >7,000 patients worth of data published since 2019 ° Low periprocedural stroke and death rates ° Lower odds cranial nerve injury ° Lower odds myocardial infarction ° Lower odds hospital stay >1 day + Vikram 8. Kashyap MD, etal. Early Outcomes
Slide 13: Efficiencies of a Less Invasive Approach
Efficiencies of a Less Invasive Approach Average Procedure Time’ h f h f h Ability to treat 67% more TCAR CEA patients vs. CEA 73Mins “ 121Mins é t é Cost of Operating Room Time? TCAR CEA ss Ss Reduced OR Time Cost $2,701 “ $4,447 over CEA: $1,776 SSsss + Annals of Surgery 2020 - M. Malas, Transcaro
Slide 14: Procedure Margin
Procedure Margin Economic Value Proposition Supporting Utilization 2021 DRG Rate: +7% 2021 DRG Rate: +4% : \ (CEA MSDRG 037-039 PROCEDURE CEA HOSPITAL TCAR MSDRG 034-036 PROCEDURE TCAR HOSPITAL REIMBURSEMENT costs’ PROCEDURE REIMBURSEMENT costs! PROCEDURE MARGIN MARGIN Hospital stay margin: TCAR fur
Slide 15: Easy-to-Learn Procedure with Many Physicians Trained
Easy-to-Learn Procedure with Many Physicians Trained Decreasing operative time with No significant differences’ in experience... major in-hospital outcomes were found regardless of experience 82 minutes level 60 minutes V4 Stroke Vj; Death Vj; Composite stroke/death/MI <5 cases >30 cases Novice Expe
Slide 16: Physician Training Pivot
16 Physician Training Pivot National TEST Q2 2020 Virtual / Drive Program ® in-person didactic @ Large cohorts hands-on Regional ® Online didactic ® Smaller group, regional hands-on MEE SILKROAD?
Slide 17: Commercial Strategy: Where Are We Now?
Commercial Strategy: Where Are We Now? Establishing TCAR in Large, Unpenetrated Opportunity US Market Share as of Q4 2017! US Market Share as of Q3 2020' 1% 6x increase Ml SILKROAD> 17 __‘Basedon Modus Health Group data for 2019 of 166k procedures and company’s reported total annual procedures as of
Slide 18: Commercial Strategy: Deepening US Adoption
Commercial Strategy: Deepening US Adoption Substantial Potential in Trained Physician Base 89 Top Quartile Physicians Adoption Curve 52 5.0 10770 . Physicians trained B40 as of YE 2020! fe) 5 S 3.0 2 : ¢ 3 20 ~55% : 15 were trained within ue last 8 quarters 0.0 0 1 2 3 4 5 6 7 8 Quarters from initia
Slide 19: Growing TCAR Adoption
19 Growing TCAR Adoption Utilization-Driven Revenue $20.1 2018 2019 2020 Ml US Procedures ——Net revenue ($mm) + Second quarter revenue in 2020 included the recognition of $1.3 million in deferred revenue due to a decrease in the provision for sales retums related to certain prior sales with a shorte
Slide 20: Meaningful Outcomes and Experiences
Meaningful Outcomes and Experiences Physician Experience with TCAR during the Pandemic “TCAR is super predictable. They’re out in 24 hours. You can keep marching these people through and prevent the disability they would have with a stroke.” “This procedure can be done reliably on incredibly sick pe
Slide 21: Ushering in a New Era of Transcarotid Therapies
Ushering in a New Era of Transcarotid Therapies SILKROAD> MEDICAL* Sole Player in Greenfield Opportunity Deepening U.S. TCAR Adoption Expanding Beyond Core Market TCAR Product Expansion Mounting Wave of © Clinical Evidence Leveraging Transcarotid Oo Expertise to Neurovascular Markets Emphasis on Eco
Slide 22: Silk Road Medical
SILKROAD> MEDICAL®
Silk Road Medical — Conference Presentation (January 2021) on 6ix